BIOSIMILARS

ARE BIOLOGIC MEDICINES THAT HELP DELIVER BETTER CARE FOR PEOPLE IN EMERGING COUNTRIES

NON-COMMUNICABLE DISEASES (NCDs), INCLUDING CANCER, ARE ON THE RISE - ESPECIALLY IN EMERGING MARKETS.[1]

NCDs, also known as chronic diseases, include conditions such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes.[1]

PERCENTAGE INCREASE OF CANCER INCIDENCE FROM 2022 TO 2050[2]

90% INDIA

83% LATIN AMERICA

49% NORTH AMERICA

25% EUROPE

By 2050 cancer incidence will increase significantly faster in **Latin America** and **India** compared with **Europe** and **North America**[2]. This is linked to economic development and changing lifestyles, leading to longer lives and higher late-life cancer risk.[1,2]

BIOLOGICS ARE CUTTING-EDGE MEDICINES THAT HAVE SIGNIFICANTLY IMPROVED THE TREATMENT OF NCDs[3]

Biologics are derived from living organisms.[4] They are highly complex molecules and more costly to produce than conventional medicines.[3,5] Hence, they may remain out of reach for many.[3]

Access to new medicines, such as biologics, is more limited in emerging countries. In fact, new medicines make up only **0.1%** of total medicines used in emerging countries, which is over **20 times less** than in developed countries.[3]

BIOSIMILARS MAKE LIFE-SAVING MEDICINES MORE ACCESSIBLE AND AFFORDABLE IN EMERGING COUNTRIES[3]

Reduced access to treatments and care in emerging countries often leads to higher disease mortality rates compared to wealthier nations.[6]

Biosimilars are high-quality, highly similar versions of reference biologics. They are launched once the originator patent expires, which brings competition and increases the availability of biologic treatments.[3]

BIOSIMILARS ARE EFFECTIVE AND SAFE AND UNDERGO A RIGOROUS REGULATORY REVIEW

Biosimilars are developed through a high-quality scientific process that demonstrates they provide the same clinical benefits as the reference biologics.[3,4]

6-9 years
The time it takes to demonstrate, through extensive testing, that a biosimilar delivers the same clinical benefits as the reference biologic.[7]

ABBOTT IS WORKING WITH EXPERTS TO EXPAND ACCESS TO BIOSIMILARS BY:

Facilitating regulatory pathways

- We've teamed up with the Americas Health Foundation and experts in cancer and health economics to tackle regulatory and policy challenges and streamline biosimilar regulatory pathways.
- This resulted in a **policy review** in *The Lancet Oncology* on streamlining biosimilars regulations to improve access to cancer treatment.[9]

Broadening access to scientific developments

- We are collaborating with local universities in Colombia on a **'Biosimilars Academy'**, which provides healthcare professionals with the latest updates on biological treatments in oncology.
- In India, our **'Start Strong'** program includes workshops to share the latest scientific developments on osteoporosis management trends with healthcare professionals.

Improving care through insights and diagnostics

- We support the use of **real-world evidence (RWE)** and diagnostic tools for timely and accurate treatment.
- In India, we're improving access to **diagnostic scans** to promote early detection and treatment of bone density issues.

AT ABBOTT, WE ARE COMMITTED TO MAKING HIGH-QUALITY BIOSIMILARS MORE ACCESSIBLE TO PEOPLE FACING SERIOUS DISEASES IN EMERGING MARKETS, SO THAT THEY CAN GET AND STAY HEALTHY.

1. The Economist Intelligence Unit. The next pandemic? Non-communicable diseases in developing countries. 2017. Accessed September 24, 2024. https://impact.economist.com/perspectives/sites/default/files/The_next_pandemic.pdf
2. IQVIA Institute for Human Data Science. Global Oncology Trends. May 28, 2024. Accessed September 24, 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024
3. Calamia M, Abraham I. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries. Expert Opin Biol Ther. 2023;23(8):653-657. doi:10.1080/14712598.2023.2247972
4. National Health Service England (NHS). What is a biosimilar medicine? September 12, 2023. Accessed September 24, 2024. https://www.england.nhs.uk/long-read/what-is-a-biosimilar-medicine/
5. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009
6. Higuchi M. United Nations (UN). UN Chronicle. Lifestyle diseases: access to chronic disease care in low- and middle-income countries. Accessed September 24, 2024. https://www.un.org/en/chronicle/article/lifestyle-diseases-access-chronic-disease-care-low-and-middle-income-countries
7. Ventola CL. Biosimilars: part 2: potential concerns and challenges for p&t committees. P T. 2013;38(6):329-335
8. Otte M, Dauben HP, Ahn J, et al. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers. Expert Rev Pharmacoecon Outcomes Res. doi:10.1080/14737167.2024.2398482
9. Teran E, Gomez H, Hannois D, Lema M, Mantilla W, Rico-Restrepo M, McElwee E, Castro Sanchez N, Valdivieso N, Espinoza MA. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. Lancet Oncol. 2022 Jul;23(7):e348-e358. doi: 10.1016/S1470-2045(22)00121-8. PMID: 35772466.